The estimated Net Worth of Pharmaceuticals Internation... is at least $200 Milione dollars as of 19 March 2018. Pharmaceuticals Internation owns over 7,420,625 units of Myovant Sciences Ltd stock worth over $200,208,463 and over the last 7 years Pharmaceuticals sold MYOV stock worth over $0.
Pharmaceuticals has made over 1 trades of the Myovant Sciences Ltd stock since 2018, according to the Form 4 filled with the SEC. Most recently Pharmaceuticals bought 7,420,625 units of MYOV stock worth $138,543,069 on 19 March 2018.
The largest trade Pharmaceuticals's ever made was buying 7,420,625 units of Myovant Sciences Ltd stock on 19 March 2018 worth over $138,543,069. On average, Pharmaceuticals trades about 7,420,625 units every 0 days since 2018. As of 19 March 2018 Pharmaceuticals still owns at least 7,420,625 units of Myovant Sciences Ltd stock.
You can see the complete history of Pharmaceuticals Internation stock trades at the bottom of the page.
Over the last 8 years, insiders at Myovant Sciences Ltd have traded over $5,780,890 worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth $2,001,605,371 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... e Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $25,106,967. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth $1,393,178,400.
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Myovant Sciences Ltd executives and other stock owners filed with the SEC include: